Cysteinyl leukotrienes (cys-LTs) are a group of lipid mediators that are potent bronchoconstrictors, powerful inducers of vascular leakage and potentiators of airway hyperresponsiveness. Cys-LTs play an essential role in asthma and are synthesized as well as activated in mast cells (MCs). Cys-LTs relay their effects mainly through two known GPCRs, CysLT1R and CysLT2R. Although protein kinase C (PKC) isoforms are implicated in the regulation of CysLT1R function, neither the role of PKCs in cys-LT-dependent MC inflammatory signaling nor the involvement of specific isoforms in MC function are known. Here, we show that PKC inhibition augmented LTD4 and LTE4-induced calcium influx through CysLT1R in MCs. In contrast, inhibition of PKCs suppressed c-fos expression as well MIP1β generation by cys-LTs. Interestingly, cys-LTs activated both PKCα and PKCε isoforms in MC. However, knockdown of PKCα augmented cys-LT mediated calcium flux, while knockdown of PKCε attenuated cys-LT induced c-fos expression and MIP1β generation. Taken together, these results demonstrate for the first time that cys-LT signaling downstream of CysLT1R in MCs is differentially regulated by two distinct PKCs which modulate inflammatory signals that have significant pathobiologic implications in allergic reactions and asthma pathology.
Citation: Kondeti V, Duah E, Al-Azzam N, Thodeti CK, Boyce JA, et al. (2013) Differential Regulation of Cysteinyl Leukotriene Receptor Signaling by Protein Kinase C in Human Mast Cells. PLoS ONE 8(8): e71536. doi:10.1371/journal.pone.0071536
Editor: Patricia T. Bozza, Fundação Oswaldo Cruz, Brazil
Received: April 15, 2013; Accepted: June 28, 2013; Published: August 15, 2013
Copyright: © 2013 Kondeti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Supported by National Institutes of Health Grants HL098953 and AI-52353, and by James Foght Assistant Professor support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Cysteinyl leukotrienes (cys-LTs), comprising LTC4, LTD4 and LTE4. are potent bronchoconstrictors and mediators of pulmonary inflammation , . They are derivatives of arachidonic acid generated by mast cells (MCs), eosinophils, basophils, macrophages, and myeloid dendritic cells . LTC4 and LTD4 are very short-lived in vivo while LTE4 is stable, being the only cys-LT detected in biologic fluids and excreted in the urine . Cys-LTs potentiate airway hyperresponsiveness (AHR) to histamine when administered by inhalation to human subjects . Bronchoalveolar lavage (BAL) fluids collected from allergic human subjects after endobronchial challenge with allergen contain high levels of cys-LTs , pointing the role of cys-LTs in allergic inflammation. This role is confirmed by the fact that inhibitors of the type 1 G protein-coupled receptor (GPCR) for cys-LTs (CysLT1R) ,  and inhibitors of cys-LT synthesis  are clinically efficacious for the treatment of asthma. Cys-LTs are also implicated in adaptive immunity and fibrosis , , . Most of these cys-LT-mediated effects are thought to be induced through CysLT1R and a second GPCR, CysLT2R , , although the existence of additional receptors is likely based on findings in mice lacking both receptors , , . Identification of signaling partners and mechanisms involved in the regulation of these receptors is crucial to gain insight into allergic inflammation.
MCs are stem cell factor (SCF)-dependent hematopoietic cells that are ubiquitously distributed throughout the body ,  and initiate inflammatory responses to allergens and infectious agents. They play an important role in triggering exacerbations of asthma through the elaboration of several soluble inflammatory mediators including cys-LTs, histamine, serine proteases, multiple cytokines and chemokines. MCs not only generate cys-LTs, but also express both CysLT1R and CysLT2R ,  and respond to LTC4, LTD4, and LTE4 with a range of functions. We have demonstrated earlier that stimulation of human cord blood-derived MCs (hMCs) and/or LAD2 cells with LTD4 potently induces calcium flux ,  and cytokine generation , , each of which requires CysLT1R based on pharmacologic antagonism by MK571. hMCs also proliferate in response to LTD4, reflecting transactivation of c-kit by CysLT1R . The relevance of cys-LTs to MC function is suggested by the observation that mice lacking the requisite terminal enzyme needed for cys-LT generation, leukotriene C4 synthase, show markedly reduced numbers of MCs in the airway mucosa following sensitization and challenge to allergen . However, aside from the ability of LTD4 to transactivate c-kit  and for LTE4 to activate PPARγ  and induce the formation of large amounts of cytokines by a pathway involving the P2Y12 receptor , little is understood concerning the signaling mechanisms by which cysteinyl leukotriene receptors modulate the function of MCs.
Protein kinase C (PKC) refers to a family of phospholipid-dependent serine/threonine protein kinases that are activated by a number of extracellular stimuli including growth factors, adhesion, cytokines and GPCRs . PKCs are involved in signal transduction associated with cell proliferation, differentiation, and apoptosis. At least eleven closely related PKC isozymes have been reported that differ in their structure, biochemical properties, tissue distribution, subcellular localization, and substrate specificity. They are classified as classical (α, β1, β2,γ), novel (δ, ε, η, θ, μ), and atypical (ξ, λ) isozymes depending on their requirement for the cofactors calcium, diacylglycerol (DAG) and phosphatidylserine (PS) , , . PKCs are implicated in the negative regulation of LTD4-induced calcium signaling , . Global pharmacological inhibition of PKCs was shown to inhibit LTD4-mediated CysLT1R internalization and desensitization resulting in enhanced phosphoinositide production and calcium flux . This CysLT1R desensitization is shown to occur mainly through the phosphorylation of three serine residues (313–316) in the tail region of CysLT1R by PKCα . In contrast, Thodeti et al., demonstrated that PKCε regulates LTD4-induced Ca2+ signal in intestinal epithelial cells . Overall, it is not clear what specific isoforms are activated by cys-LTs in MCs or how they are involved in regulation of the LTD4-induced Ca2+ signal as well MC activation. In the present study, we investigated the specific PKC isoforms activated in MCs by cys-LTs and the role of each isoform in regulating cys-LT-induced MC responses. We show that both LTD4 and LTE4 activate PKCα and PKCε isoforms and that these isoforms regulate different signals down-stream of CysLT1R. Specifically, PKCα negatively regulates cys-LT-induced calcium flux, while PKCε positively regulates CysLT1R-mediated c-fos expression and MIP1β generation.
Materials and Methods
LTD4, LTE4 and MK571 were purchased from Cayman Chemical. Fura-2 AM was from Molecular Probes, All phospho-specific antibodies were from Cell Signaling Technology, Total PKC antibodies were from Santa Cruz Biotechnology. Isoform specific siRNAs for PKCs were obtained from Dharmacon and MIP1β Elisa kit was from Endogen.
The LAD2 MC leukemia line  was a kind gift from Dr. Arnold Kirshenbaum, NIH. These cells were cultured in stempro-34 (Invitrogen) supplemented with 2 mM L-Glutamine (Invitrogen), Pen-strep (100 IU/ml) (Invitrogen) and SCF (endogen) (100 ng/ml). Cell culture medium was hemidepleted every week with fresh medium and 100 ng/ml SCF. Primary hMCs were derived from cord blood mononuclear cells cultured for 6–9 weeks in RPMI supplemented with SCF, interleukin IL-6, and IL-10 .
LAD2 cells or hMCs (0.5–1×106/sample) were washed and labeled with fura 2-AM for 30 minutes at 37°C. Cells were stimulated with the indicated concentrations of LTD4 and LTE4 and the changes in intracellular calcium were measured using excitation at 340 and 380 nm in a fluorescence spectrophotometer (Hitachi F-4500) as described earlier . The relative ratios of fluorescence emitted at 510 nm were recorded and displayed as a reflection of intracellular calcium concentration. In some experiments, cells were pre-incubated with the PKC inhibitor GF109203X (GFX; 2 µM) for 30 minutes or with CysLT1R antagonist MK571 (1 µM) for 15 minutes before the stimulation with cys-LTs (500 nM).
LAD2 cells were either stimulated with 500 nM of LTD4 or LTE4 (unless specified otherwise), pre-treated with GFX (2 µM) for 30 minutes or MK571 (1 µM) and stimulated for 15 minutes for the phosphorylation of Erk and CREB or 1 h for the expression of c-fos or 6 h for the measurement of cytokines. The concentration of MIP1β (Endogen) was measured with ELISAs according to the manufacturer’s protocol . Transfection of isoform specific siRNA smart pool constructs from Dharmocon (10 nM) were carried out using Silentfect transfection reagent (Biorad) for 48 h according to the manufacturer’s protocol.
Cell Lysates and Western Blotting
After stimulation with the respective agonists, LAD2 cells (0.5×106) were lysed with lysis buffer (BD Bioscience) supplemented with protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (pierce). Immunoblotting was performed as described previously . Briefly, lysates were subjected to 4–12% SDS-PAGE and transferred to PVDF membrane. Membranes were incubated with respective primary Phospho- and total antibodies diluted in 1x TBS, 5% dry milk, 0.1% Tween-20 (1:1000) overnight at 4°C on shaker, and then with secondary antibody (peroxidase-conjugated anti-rabbit or anti-mouse). Western blot was incubated with ECL and the bands were visualized using imager (Protein Simple) and quantified using Image J (NIH).
Data are expressed as mean ± SD from at least three experiments except where otherwise indicated. Data were converted to a percentage of control for each experiment where indicated. Significance was determined using Student’s t test as well as one-way ANOVA followed by Tukey post-hoc analysis.
Cys-LT-mediated Calcium Flux in Mast Cells is Negatively Regulated by PKC
We have reported earlier that cys-LTs, especially LTD4, potently induces calcium flux in primary hMCs  and also in LAD2 cells . This signal was sensitive to inhibition by MK571, implying a requirement for CysLT1R or a CysLT1R-like GPCR in this signaling event. CysLT1R undergoes ligand-induced desensitization and internalization in heterologous cell systems and these processes are uniquely dependent on PKC . Based on these observations, we sought to determine if PKCs have a role in controlling cys-LT-dependent calcium flux in MCs. Both hMCs and LAD2 cells were pre-treated with GF109203X (GFX), a global PKC inhibitor, and its effect on LTD4 or LTE4 stimulation was evaluated. In the absence of GFX, LTD4 (500 nM) potently stimulated calcium flux in both cell types, but LTE4 (500 nM) only caused minimal calcium flux. However, GFX treatment markedly potentiated LTD4 and LTE4-mediated calcium fluxes in both cell types (Fig. 1 A, B). Importantly, a specific antagonist of CysLT1R, MK-571, completely abolished both LTD4 and LTE4-mediated calcium fluxes in the presence of GFX (Fig. 1C). These observations suggest that the strength of calcium signaling through CysLT1R is negatively regulated by PKCs, probably through the desensitization of the receptors , .
Calcium transients from hMC (A) and LAD2 cells (B) with cys-LTs (500 nM) in presence or absence of PKC inhibitor, GFX (2 µM) (C) Quantitative analysis of calcium influx from A and B and the effect of MK571 (1 µM) on the enhanced calcium flux with GFX pre-treatment. The data shown are±SD of three experiments. The significance was tested using Student’s t-test as well as one-way ANOVA followed by Tukey post-hoc analysis. P<0.05. NS = non-significant.
PKCs are Required for cys-LT-mediated Phosphorylation and Expression of c-fos
In rat basophilic leukemia (RBL) cells, Ng et al., demonstrated that disrupting CysLT1R desensitization by PKC inhibitors can lead to enhanced LTC4-induced calcium influx, but prevents up-regulation of c-fos expression through the CRAC channels. Along these lines, we first checked if stimulation of MCs with LTD4 and LTE4 induced c-fos expression (Fig. 2). We found that both LTD4 and LTE4 induced robust activation of c-fos at the transcript level as well as at the protein level. Surprisingly, the induction of c-fos transcript was maximum at 30 minutes, while the protein induction was as early as 30 minutes with peak expression at 1 h and then slowly began to decline after stimulation with either LTD4 or LTE4 (Fig. 2A, B). To determine the potency of cys-LTs to induce the expression of c-fos, we treated LAD2 cells with various concentrations of LTD4 and LTE4 and analyzed phosphorylation and induction of c-fos (Fig. 2C). LTD4 caused c-fos induction at doses as low as 1 nM while LTE4 evoked similar response at relatively higher concentrations (100 nM and 500 nM). On average, we found that 500 nM concentration of cys-LTs evoked the best response of all the experiments performed and hence we stimulated cells with 500 nM of cys-LTs in all the concurrent experiments. Also, we observed that the pattern of phosphorylation as well as expression of c-fos were similar with both LTD4 and LTE4, suggesting that cys-LTs not only induced the expression of c-fos but also activated c-fos. We then asked if cys-LT-induced c-fos expression and activation are sensitive to PKC inhibition and are mediated through cysLT1R. Both LTD4 and LTE4-induced c-fos activation as well as expression was inhibited by GFX as well as MK571 (Fig. 2D). These results suggest that though PKCs negatively regulate cys-LT-mediated calcium flux, but are required for cys-LT-mediated c-fos phosphorylation/expression.
Relative levels of c-fos transcript (A) upon treatment with 500 nM of LTD4 and LTE4, c-fos phosphorylation and expression with LTD4 or LTE4 (500 nM) for indicated period (B), Dose response (C), Pre-treated with GFX (2 µM) or MK571 (1 µM) (D), stimulated with 500 nM of cys-LTs and analyzed by western blotting. Blots were stripped and blotted for GAPDH. The data shown are representative of three separate experiments.
MIP1β Generation by cys-LTs is Positively Regulated by PKCs
Next, we investigated the effect of PKC inhibition on other cys-LT-induced MC functions. We have shown earlier that cys-LTs are capable of potently activating inflammatory chemokine, MIP1β in MCs . Hence, we asked if PKCs play a role in cys-LT-induced inflammatory responses such as MIP1β production in MCs. To determine this, LAD2 cells were pre-treated with GFX with or without cys-LT stimulation and MIP1β was measured in the supernatants. As reported earlier  and shown in Fig. 3, both LTD4 and LTE4 potently induced MIP1β generation. Importantly, unlike calcium flux, MIP1β induction by both the agonists was significantly blocked by PKC inhibition with GFX (Fig. 3). These findings suggest the PKCs differentially regulate cys-LT-induced calcium influx and gene expression in MCs, possibly via activation of distinct isoforms of PKCs.
LAD2 cells were stimulated with 500 nM of LTD4 or LTE4 for 6 h in presence or absence of GFX (2 µM). The generation of MIP1β was analyzed from the culture supernatant using MIP1β-specific ELISA. Data shown are±SD of three independent experiments. ** P<0.001. NS = non-significant.
PKCs do not Effect cys-LT-activated ERK, or CREB Pathways
We have shown earlier that cys-LTs activate ERK and CREB  and we sought to investigate if all cys-LT-induced effects are mediated through PKCs. To our surprise, PKC inhibition by GFX had no significant effect on the phosphorylation or the expression of ERK and CREB by cys-LTs (Fig. 4). These results suggest that cys-LTs have potential to modulate MC function, both dependent as well as independent of PKCs.
(A) phosphorylation as well as total expression of Erk and CREB proteins by Western blotting in cell lysates of LAD2 cells pre-treated with GFX (2 µM) and stimulated with 500 nM of LTD4 and LTE4 respectively for 30 minutes (B) Quantitative analysis. The shown data represents±SD of three separate experiments. *P<0.05. NS = non-significant.
PKC Profile in MCs and Identification of cys-LT-responsive PKC Isoforms
To determine which of the PKC isoforms mediate cys-LT signaling responses, we first characterized the expression of different isoforms of PKCs in MCs including classical PKCs (α, βI, βII, γ), novel PKCs (δ, ε, η, θ), and atypical PKCs (ζ, ι/λ, μ) by Western blotting. We found that MCs express PKC α, βII, γ, δ, ε, θ and ζ isoforms (Fig. 5A) and not βI, η, ι/λ, μ (data not shown). We next asked which of the expressed PKC isoforms are activated by cys-LTs. Cys-LT responsive PKC isoforms were determined by analyzing the phosphorylation of individual PKC isoforms in response to cys-LTs using phospho-specific antibodies. We found that PKCα and PKCε are phosphorylated by both LTD4 and LTE4 in a time dependent manner (Fig. 5B, C), but not PKC βII, γ, δ, θ and ζ isoforms (data not shown). Phosphorylation of both PKCα and PKCε in response to cys-LTs was rapid and transient reaching a peak at 15 minutes and started to decline after 30 minutes. The peak LTE4-induced phosphorylation of PKCε, but not of PKCα was more gradual than that induced by LTD4. The small inhibition in the phosphorylation of PKCε that we observed at 10 minutes compared to 5 minutes in response to LTE4 is not statistically significant.
(A) Expression of PKC isoforms and GAPDH (B) phosphorylation of PKCα and PKCε stimulated with 500 nM of LTD4 or LTE4 for the indicated times (C) Quantitative analysis of relative phospho-PKC levels in LAD2 cells. Data shown are±SD of three separate experiments.
PKCα Negatively Regulates cys-LT Mediated Calcium Flux While PKCε is Essential for MIP1β Generation by cys-LTs
After determining that LTD4 and LTE4 both activated PKCα and PKCε in MCs, we investigated the specific roles of PKCα and PKCε in cys-LT-mediated calcium flux, c-fos expression and MIP1β production (Fig. 6). To determine this, we first knocked down PKCα and PKCε isoforms in LAD2 cells by transfecting isoform specific siRNAs (10 nM) against PKCα and PKCε. As a control, we transfected cells with a non-specific siRNA pool. Transfection of MCs with PKCα and PKCε siRNAs significantly down regulated PKCα and PKCε expression (40.0±4.3% and 41.5±9.2% down regulation), respectively (Fig. 6A). Down regulation of PKCα with PKCα siRNA did not have any significant effect on the expression of PKCε and vice versa (data not shown). We then assessed cys-LT mediated calcium influx, c-fos phosphorylation, expression and MIP1β generation in these cells. Calcium measurements revealed that knock down of PKCα induced a significant two fold increase in LTD4-induced peak calcium influx in MCs (Fig. 6B, C). We did not detect any change in calcium flux induced by LTD4 in PKCε knocked-down MCs suggesting that PKCα is the key isoform involved in the negative regulation of cys-LT induced calcium flux. On the other hand, knockdown of PKCε attenuated both LTD4 and LTE4-induced c-fos expression (Fig. 6D, E) and phosphorylation (data not shown). Knock down of PKCε also attenuated cys-LT-induced MIP1β production in MCs (53% and 55% respectively) (Fig. 6F). Transfection with control siRNAs did not affect LTD4 and LTE4-induced c-fos expression or MIP1β generation. Although PKCα knock down marginally inhibited MIP1β generation, this signal is not significantly different from control siRNA.
PKCα and PKCε isoforms were Knocked down using specific siRNAs against PKCα and PKCε (10 nM). Non-specific (NS) siRNA was used as a control. The siRNA treated cells were analyzed for (A) the expression of PKCα, PKCε and GAPDH, (B, C) LTD4 (500 nM)-induced calcium influx, and quantitative analysis, (D, E) cys-LT-induced c-fos expression, (F) MIP1β production. Cells were treated with 500 nM of LTD4 and LTE4 for 5 minutes (calcium flux), 1 h (c-fos expression) and 6 h (MIP1β). Data shown are±SD of three separate experiments. *P<0.05, **P<0.001.
In the present study, we demonstrate that cys-LTs activate two isoforms of protein kinases, PKCα and PKCε and that these two isoforms differentially regulate cys-LT-mediated MC function. PKCε is essential for cys-LT-mediated c-fos expression and MIP1β generation, while PKCα negatively regulates cys-LT-induced calcium flux (schematic, Fig. 7). Surprisingly, PKCs appear to be dispensable for expression and activation of ERK and CREB.
Hypothetical mechanism(s) depicting cys-LT-mediated signaling in MCs by PKCs. CysLT1R activation by LTD4 or LTE4 activates PKCα and PKCε. PKCα desensitize CysLT1R by phosphorylating the receptor and negatively regulating the calcium flux. On the other hand, PKCε activation by CysLT1R activates c-fos expression, MIP1β production. Cys-LTs also activate Erk and CREB independent of PKCs.
MCs are relevant cellular effectors of asthma and other allergic diseases, and cys-LTs are pertinent mediators of the same processes . The mechanisms that control cys-LT-dependent biological responses are of considerable pathobiologic and clinical interest in both allergic and non-allergic disease . We have previously demonstrated that cys-LTs induce robust calcium flux in hMCs ,  and LAD2 cells via CysLT1R (based on pharmacologic interference using selective antagonists) . We have shown earlier that MK571 specifically blocks calcium flux and Erk phosphorylation in CHO cells expressing CysLT1R, but not CysLT2R suggesting its specificity . MK571 is also reported to have inhibitory activity against MRP1 . Further, it was shown that MK571 treatment increased intracellular LTC4 concentration in eosinophils and modulate IL-4 levels from preformed vesicles via a putative intracellular CysLT receptor . However, cys-LT-induced inflammatory mediator production in MCs require de novo transcriptional and translational mechanisms and no such putative intracellular CysLTR has been identified. Therefore, we believe that the observed inhibitory effects of MK571 are mostly directed at CysLT1 receptor on the plasma membrane. In the current study, we elucidate that pharmacological inhibition of PKCs followed by stimulation of cells with cys-LTs resulted in significant augmentation of calcium flux in MCs. This finding is consistent with desensitization of CysLT1R by PKCs reported in other cell systems. Crooke and colleagues observed that LTD4 activates PKC, and the same research team ,  noted that inhibitors of PKC increased the mobilization of Ca2+ induced by LTD4 in the leukemic cell line RBL-1 using pharmacological activators and inhibitors. Winkler et al.  have reported that the broad PKC inhibitor staurosporine potentiated the LTD4-induced Ca2+ signal in differentiated U-937 cells. In COS-1 cells overexpressing CysLT1R, pharmacological inhibition of PKC activity was shown to enhance calcium mobilization stimulated by LTD4 . However the exact molecular mechanism(s) underlying this process are not well known.
Enhanced receptor activation is usually translated into increased receptor function. Relief of PKC-mediated desensitization of endogenous CysLT1R augments multiple LTD4-stimulated cellular functions, with associated increases in intracellular signaling events . However, while our data indicate that PKC inhibition augmented cys-LT-induced calcium signaling, we also found that it suppressed cys-LT-induced c-fos expression and chemokine secretion. Activation of c-fos by LTD4 has been reported previously in HEK cells expressing CysLT1R . Recently, Ng et al., reported that LTC4-mediated CysLT1R is desensitized by PKC-dependent phosphorylation and that prevention of this signaling by PKC inhibition led to loss of calcium-dependent gene expression, despite potentiation of Ca2+ release . This signal was proposed to delay the activation of CRAC channels resulting in the decreased c-fos expression. In the present study using LAD2 cells, we observed that both LTD4 and LTE4 significantly increased the expression of c-fos, consistent with the earlier study . Our data demonstrate that LTD4 and LTE4 also induce c-fos phosphorylation. This increase in phosphorylation and expression of c-fos is mediated through an MK-571 sensitive CysLTR and PKC. Since cys-LTs activate both Erk and CREB , we investigated if PKC inhibition altered cys-LT-mediated phosphorylation of these signaling molecules. Although cys-LTs robustly enhanced phosphorylation of Erk and CREB, inhibition of PKCs surprisingly had no effect on this signal. These findings suggest that modulation of PKC activity may couple CysLTR signaling to distinct signaling pathways. It is also possible that at least some of the PKC-independent signaling events may occur through receptors other than CysLT1R.
Despite the fact that cys-LT-mediated calcium signaling was enhanced by global PKC inhibition (Fig. 1), c-fos expression and MIP1β generation was substantially suppressed. While this finding could reflect a requirement for CysLT1R receptor desensitization to facilitate gene induction as suggested by the Ng et al., it also suggested that cys-LTs activate more than one PKC isoform in MCs. Indeed, we found that MCs express PKC α, βII, γ, δ, ε, θ and ζ isoforms but only PKCα and PKCε were phosphorylated in response to cys-LTs. Notably, we found that PKCα knockdown significantly augments calcium flux, but has little effect on cys-LT-induced c-fos and MIP1β production. However, knockdown of PKCε significantly attenuated cys-LT-induced c-fos phosphorylation, expression and MIP1β production without altering calcium flux. Activation of PKCε by cys-LTs has been showed in other systems , ,  as well. Interestingly, PKCε was shown to be essential for LTD4-induced calcium signal in intestinal epithelial cells, suggesting that coupling of cys-LTs to signaling events is regulated in a cell type-specific manner. In conclusion, our study identifies specific isoforms of PKCs, PKCα and PKCε that are activated by cys-LTs and differentially regulate distinct MC functions, critical for the progression and pathology of asthma. Understanding the signaling and players involved in CysLTR regulation can be useful in identifying better therapeutic targets for inflammatory asthma and allergic diseases.
Conceived and designed the experiments: SP JAB CKT VK ED NA. Performed the experiments: SP VK ED NA. Analyzed the data: SP VK ED NA. Contributed reagents/materials/analysis tools: SP JAB CKT. Wrote the paper: SP JAB CKT VK ED NA.
- 1. Davidson AB, Lee TH, Scanlon PD, Solway J, McFadden ER Jr, et al. (1987) Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis 135: 333–337.
- 2. Drazen JM, Austen KF (1987) Leukotrienes and airway responses. Am Rev Respir Dis 136: 985–998. doi: 10.1164/ajrccm/136.4.985
- 3. Kanaoka Y, Boyce JA (2004) Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 173: 1503–1510.
- 4. Drazen JM, O’Brien J, Sparrow D, Weiss ST, Martins MA, et al. (1992) Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 146: 104–108. doi: 10.1164/ajrccm/146.1.104
- 5. Christie PE, Hawksworth R, Spur BW, Lee TH (1992) Effect of indomethacin on leukotriene4-induced histamine hyperresponsiveness in asthmatic subjects. Am Rev Respir Dis 146: 1506–1510. doi: 10.1164/ajrccm/146.6.1506
- 6. Wenzel SE, Larsen GL, Johnston K, Voelkel NF, Westcott JY (1990) Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 142: 112–119. doi: 10.1164/ajrccm/142.1.112
- 7. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, et al. (1998) A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 102: 50–56. doi: 10.1016/s0091-6749(98)70054-5
- 8. Hamilton A, Faiferman I, Stober P, Watson RM, O’Byrne PM (1998) Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 102: 177–183. doi: 10.1016/s0091-6749(98)70083-1
- 9. Israel E, Cohn J, Dube L, Drazen JM (1996) Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. Jama 275: 931–936. doi: 10.1001/jama.275.12.931
- 10. Beller TC, Friend DS, Maekawa A, Lam BK, Austen KF, et al. (2004) Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci U S A 101: 3047–3052. doi: 10.1073/pnas.0400235101
- 11. Beller TC, Maekawa A, Friend DS, Austen KF, Kanaoka Y (2004) Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 279: 46129–46134. doi: 10.1074/jbc.m407057200
- 12. Kim DC, Hsu FI, Barrett NA, Friend DS, Grenningloh R, et al. (2006) Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J Immunol 176: 4440–4448. doi: 10.4049/jimmunol.176.7.4440
- 13. Heise CE, O’Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, et al. (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275: 30531–30536. doi: 10.1074/jbc.m003490200
- 14. Lynch KR, O’Neill GP, Liu Q, Im DS, Sawyer N, et al. (1999) Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399: 789–793.
- 15. Austen KF, Maekawa A, Kanaoka Y, Boyce JA (2009) The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 124: 406–414; quiz 415–406.
- 16. Maekawa A, Kanaoka Y, Xing W, Austen KF (2008) Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 105: 16695–16700. doi: 10.1073/pnas.0808993105
- 17. Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W, et al. (2009) Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 206: 2543–2555. doi: 10.1084/jem.20091240
- 18. Gurish MF, Boyce JA (2006) Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. J Allergy Clin Immunol 117: 1285–1291. doi: 10.1016/j.jaci.2006.04.017
- 19. Wedemeyer J, Tsai M, Galli SJ (2000) Roles of mast cells and basophils in innate and acquired immunity. Curr Opin Immunol 12: 624–631. doi: 10.1016/s0952-7915(00)00154-0
- 20. Mellor EA, Frank N, Soler D, Hodge MR, Lora JM, et al. (2003) Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proc Natl Acad Sci U S A 100: 11589–11593. doi: 10.1073/pnas.2034927100
- 21. Mellor EA, Maekawa A, Austen KF, Boyce JA (2001) Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci U S A 98: 7964–7969. doi: 10.1073/pnas.141221498
- 22. Paruchuri S, Jiang Y, Feng C, Francis SA, Plutzky J, et al. (2008) Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem 283: 16477–16487. doi: 10.1074/jbc.m705822200
- 23. Mellor EA, Austen KF, Boyce JA (2002) Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med 195: 583–592. doi: 10.1084/jem.20020044
- 24. Jiang Y, Kanaoka Y, Feng C, Nocka K, Rao S, et al. (2006) Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. J Immunol 177: 2755–2759. doi: 10.4049/jimmunol.177.5.2755
- 25. Jaken S, Parker PJ (2000) Protein kinase C binding partners. Bioessays 22: 245–254. doi: 10.1002/(sici)1521-1878(200003)22:3<245::aid-bies6>3.0.co;2-x
- 26. Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332 (Pt 2): 281–292.
- 27. Newton AC (1997) Regulation of protein kinase C. Curr Opin Cell Biol. 9: 161–167. doi: 10.1016/s0955-0674(97)80058-0
- 28. Nishizuka Y (1995) Protein kinase C and lipid signaling for sustained cellular responses. Faseb J 9: 484–496.
- 29. Vegesna RV, Wu HL, Mong S, Crooke ST (1988) Staurosporine inhibits protein kinase C and prevents phorbol ester-mediated leukotriene D4 receptor desensitization in RBL-1 cells. Mol Pharmacol 33: 537–542.
- 30. Winkler JD, Sarau HM, Foley JJ, Crooke ST (1990) Inhibitors of protein kinase C selectively enhanced leukotriene D4-induced calcium mobilization in differentiated U-937 cells. Cell Signal 2: 427–437. doi: 10.1016/0898-6568(90)90039-d
- 31. Naik S, Billington CK, Pascual RM, Deshpande DA, Stefano FP, et al. (2005) Regulation of cysteinyl leukotriene type 1 receptor internalization and signaling. J Biol Chem 280: 8722–8732. doi: 10.1074/jbc.m413014200
- 32. Thodeti CK, Nielsen CK, Paruchuri S, Larsson C, Sjolander A (2001) The epsilon isoform of protein kinase C is involved in regulation of the LTD(4)-induced calcium signal in human intestinal epithelial cells. Exp Cell Res 262: 95–103. doi: 10.1006/excr.2000.5077
- 33. Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, et al. (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27: 677–682. doi: 10.1016/s0145-2126(02)00343-0
- 34. Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, et al. (1999) T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 190: 267–280. doi: 10.1084/jem.190.2.267
- 35. Paruchuri S, Hallberg B, Juhas M, Larsson C, Sjolander A (2002) Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells. J Cell Sci 115: 1883–1893.
- 36. Ng SW, Bakowski D, Nelson C, Mehta R, Almeyda R, et al. (2012) Cysteinyl leukotriene type I receptor desensitization sustains Ca2+-dependent gene expression. Nature 482: 111–115. doi: 10.1038/nature10731
- 37. Boyce JA (2003) Mast cells: beyond IgE. J Allergy Clin Immunol 111: 24–32; quiz 33.
- 38. Laidlaw TM, Boyce JA (2012) Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy 42: 1313–1320. doi: 10.1111/j.1365-2222.2012.03982.x
- 39. Rius M, Hummel-Eisenbeiss J, Keppler D (2008) ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4). J Pharmacol Exp Ther 324: 86–94. doi: 10.1124/jpet.107.131342
- 40. Bandeira-Melo C, Woods LJ, Phoofolo M, Weller PF (2002) Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med 196: 841–850. doi: 10.1084/jem.20020516
- 41. Vegesna RV, Mong S, Crooke ST (1988) Leukotriene D4-induced activation of protein kinase C in rat basophilic leukemia cells. Eur J Pharmacol 147: 387–396. doi: 10.1016/0014-2999(88)90173-2
- 42. Deshpande DA, Pascual RM, Wang SW, Eckman DM, Riemer EC, et al. (2007) PKC-dependent regulation of the receptor locus dominates functional consequences of cysteinyl leukotriene type 1 receptor activation. Faseb J 21: 2335–2342. doi: 10.1096/fj.06-8060com
- 43. Thompson C, Cloutier A, Bosse Y, Thivierge M, Gouill CL, et al. (2006) CysLT1 receptor engagement induces activator protein-1- and NF-kappaB-dependent IL-8 expression. Am J Respir Cell Mol Biol 35: 697–704. doi: 10.1165/rcmb.2005-0407oc
- 44. Paruchuri S, Sjolander A (2003) Leukotriene D4 mediates survival and proliferation via separate but parallel pathways in the human intestinal epithelial cell line Int 407. J Biol Chem 278: 45577–45585. doi: 10.1074/jbc.m302881200